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A 10-year-old boy presented with a 3-day history of worsening abdominal pain, fever, emesis and melena. Abdominal ultrasound
revealed a right upper quadrant mass that was conﬁrmed by computed tomography angiogram (CTA), which showed an 8cm
well-deﬁned retroperitoneal vascular mass. 123Iodine metaiodobenzylguanidine (123MIBG) scan indicated uptake only in the
abdominalmass.Subsequentbiopsyrevealedaparagangliomathatwastreatedwithchemotherapy.Thiscaserepresentsanunusual
presentation of a paraganglioma associated with gastrointestinal (GI) bleeding and highlights the utility of CTA and 123MIBG in
evaluation and treatment.
1.Introduction
Paragangliomas are rare tumors of neuroendocrine lin-
eage with the potential for malignant progression. Among
neuroendocrine tumors, paragangliomas may initially grow
insidiously, lacking biochemical secretion [1], and therefore
present with nonspeciﬁc symptoms dependent upon the site
of origin. Abdominal paragangliomas typically present with
signs of catecholamine hypersecretion and less often with
tumor mass eﬀects such as abdominal pain [2]. We report
a case of vascular duodenal paraganglioma in a 10-year-old
boy presenting with GI bleeding with the tumor invading the
GI tract detected by CTA and 123MIBG imaging.
2.CaseReport
A previously healthy 10-year-old African American boy
presented with a 3-day history of fever and periumbilical
abdominal pain and a 24-hour history of nonbloody, nonbil-
ious emesis, tenesmus, and melena. Past medical and family
histories were noncontributory. In the emergency room,
he was dehydrated, afebrile, tachycardic, and normotensive.
Abdominal exam was soft, with mild epigastric tenderness,
without appreciable hepatosplenomegaly or masses. Stool
was hemoccult positive. Initial laboratory studies were sig-
nificant for hemoglobin 4g/dL (13–16), MCV 80.1fL (78–
98), BUN 12mg/dL (7–18), creatinine 0.8mg/dL (0.3–0.8),
and albumin 2.7g/dL (3.7–5.6). Coagulation factors were
normal but inﬂammatory markers were slightly elevated.
Stool bacterial, viral, and parasitic pathogens were negative.
Initial management included intravenous ﬂuids rehydration
followed by packed red blood cells. He was admitted to the
GI service for further workup. Within 8 hours of presenta-
tion, abdominal examination suggested a new right upper
quadrant fullness that quickly progressed from a doughy
consistency to a discrete, dense 10cm round mass in the
middle of the abdomen. A broad diﬀerential diagnosis for
GI bleeding and abdominal pain was entertained, including
infectious etiologies, inﬂammatory bowel disease, Meckel’s
diverticulum, and malignancies. An extensive workup to
investigate these possibilities followed.
Abdominal radiograph showed midline displacement
of bowel loops. Abdominal ultrasound revealed a right
upper quadrant mass displacing the pancreatic head and2 Case Reports in Pediatrics
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Figure 1:(a)Abdominalradiographshowsmidlinedisplacementofbowelloopsbyasofttissuedensity(blackarrows)withoutcalciﬁcations
and no bowel obstruction. (b) Coronal CTA shows the markedly enhancing mass (orange arrowhead) displacing the aorta (A) and IVC (I)
and its close proximity to the 3rd portion of the duodenum (yellow arrow). (c) A maximum intensity projection from the CTA depicts
gastroduodenal artery GD (arrow) as the primary feeder of the paraganglioma.
compressing the inferior vena cava (IVC). CTA indicated an
8cm well-deﬁned retroperitoneal mass. This highly vascular
mass closely abutted the third portion of the duodenum
with poor deﬁnition of the fat planes between mass and
bowel, signiﬁcantly compressing the IVC. The lesion was
primarily fed by the gastroduodenal and superior mesenteric
arteries. The mass also abutted the right kidney, resulting in
pelvicaliectasis Figures 1(a)–1(c).
Given the concern for a GI tumor, staging evaluation
including chest CT, brain magnetic resonance imaging
(MRI), bone scan, and bone marrow biopsy were per-
formed, all negative. 123MIBG scan indicated uptake only
in the abdominal mass. Urinary catecholamines and tumor
markers such as alpha-fetoprotein were negative. A CT-
guided biopsy with histology and electron microscopy were
consistent with a neuroendocrine tumor, speciﬁcally, a
paraganglioma.
Over the course of 24 hours, he underwent exploratory
laparotomy, which revealed a mass densely adherent to the
third portion of the duodenum. Deﬁnitive upfront resection
was deferred. Two cycles of neoadjuvant chemotherapy
(vincristine, cyclophosphamide, and doxorubicin) resulted
in no change in the mass size or degree of 123MIBG uptake.
Surgical resection 5 months later revealed a tumor adherent
to the inferior mesenteric vein, aorta, mesenteric vessels,
vena cava, and ureter, which were dissected away. At the
duodenal adhesion, a malignant ulcer was eroding into the
third part of the duodenum. Near total gross resection
with positive microscopic margins and negative lymph node
sampling was achieved. Genetic testing revealed a germlineCase Reports in Pediatrics 3
point mutation in the mitochondrial complex II enzyme
succinate dehydrogenase (SDH)g e n e , subunit B.
3. Discussion
After the ultrasound and CT imaging, the diﬀerential was
modiﬁed to include invasive GI tumors, including stromal
tumors (GIST), neuroendocrine tumors, embryonal tumors,
g e r mc e l lt u m o r s ,o rt u m o r so fn e r v es h e a t ho r i g i n .R a r e l y ,
tumors are associated with GI bleeding when eroding
through intestinal mucosa [3].
Paragangliomas are exceedingly rare chromaﬃnt i s s u e
complexes of the neuroendocrine system, distributed along
paravertebralandparaaorticaxes.Paragangliomascommon-
ly occur in the region between the inferior mesenteric artery
and aortic bifurcation known as the organ of Zuckerkandl
but can occur in all locations where paragangliomas are
found [2, 4]. Paragangliomas can be either functional (sym-
pathetic) or nonfunctional (parasympathetic) depending on
the site of origin [2]. Paragangliomas are more frequent in
adults, with few pediatric cases [5, 6]. Approximately 10–
20% of pheochromocytomas and paragangliomas are diag-
nosed in childhood, with a slight predominance in males,
particularly under the age of 10 [2]. Common presenting
symptoms include GI bleeding, abdominal pain, and bilious
emesis from obstruction [5]. Paragangliomas most often
arise sporadically, with 10% arising in the setting of a
hereditary predisposition [7]. Early age of onset, multifocal
and bilateral tumors are more consistently associated with
germline mutations, with rates of germline mutations in
children younger than 10 years approaching 70% [7].
The speciﬁc gene defects associated with paraganglioma
development involve the B, C, and D subunits of the SDH
gene. While both B and D mutations increase the risk
of malignant progression as compared to sporadic cases,
SDHB-positive tumors are more aggressive [8–12], with
nearly 70% eventually becoming metastatic [10]. Not only
is the presence of an SDHB mutation considered to be a
risk factor for development of metastatic disease, but it may
also predispose to presentation of disease at an extra-adrenal
location as well as at a younger age. Metastases have been
identiﬁed in bones, liver, lungs, and lymph nodes. In a recent
cohort study, the majority of patients had metastases to
the bones, and all patients with SDHB mutations had at
least one metastatic lesion to the bones [13]. Outcome in
this group is typically poor [12]. Unbalanced chromosomal
aberrations particularly in chromosome 11, 11p, and 1p
are thought to be involved in childhood paragangliomas;
aberrations in chromosome 11 are more common in malig-
nant tumors [14]. Therefore, genetic testing of the index
case and potentially aﬀected family members is critical for
management, surveillance, and genetic counseling. Patients
and carriers of SDH mutations require long-term imaging
surveillance of the neuroaxis, and routine surveillance for
plasma catecholamine metabolites [8].
Radiographically, CT or MRI is the initial test of choice.
Paragangliomas are vascular tumors that commonly contain
necrotic, cystic, or hemorrhagic areas that can be identiﬁed
by MRI. 123MIBG is a highly speciﬁc test that detects the
catecholamine-secreting nature of a tumor. As 123MIBG test-
ing is not 100% sensitive, other nuclear imaging modalities
should be considered. [18F]FDG PET (positron emission
tomography) is the preferred functional imaging modality
for staging and treatment of SDHB-positive paraganglioma
[15].
Treatment for localized paraganglioma is primarily sur-
gical. For unresectable or metastatic paragangliomas, no
clear standard of care exists. When indicated, sarcoma-like
therapies are often employed. Combinations of cyclophos-
phamide, vincristine, and dacarbazine have been shown to
induce tumor regression; however, the survival beneﬁts of
such therapy is unclear and has the potential for signiﬁcant
late eﬀects in adolescent patients [16]. Experimental thera-
pies employing high-dose 131MIBG (131iodine metaiodoben-
zylguanidine) are currently being evaluated for patients with
metastases [17], and targeted small molecules that impact
angiogenesis, such as sunitinib, may eventually prove to have
utility in this disease [18].
Our patient had an SDHB-related paraganglioma. Pa-
rental testing revealed an identical mutation in the patient’s
mother, who has not experienced any tumors to date.
Three of the patient’s siblings have been tested and 2 carry
germline SDHB mutations and are currently undergoing
tumor surveillance. He has had follow-up imaging including
MRI and 123MIBG exams every six months as well as annual
head, neck, and chest imaging for metachronous tumors
along the neuroendocrine axis. The patient was treated with
3c o u r s e so f131MIBG therapy and is currently in remission
on maintenance therapy with oral sunitinib.
In summary, gastrointestinal bleeding from paragan-
glioma invading the duodenum is extremely rare in children.
Although rare, neuroendocrine tumors should be enter-
tained in the diﬀerential diagnosis of pain or GI bleeding,
speciﬁcally if associated with an abdominal mass. Combina-
tions of imaging techniques are key in the correct identiﬁca-
tion, characterization, evaluation, and management of these
tumors.
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